Skip to main content
. Author manuscript; available in PMC: 2014 Mar 15.
Published in final edited form as: Sci Transl Med. 2013 Jun 19;5(190):190ra79. doi: 10.1126/scitranslmed.3005471

Fig. 6. Effect of clomiphene and toremifene on VLP entry.

Fig. 6

(A and B) Clomiphene (A) and toremifene (B) were tested for their ability to inhibit VLPs with the EBOV GP1,2 glycoprotein (VLP-GP), the VSV-G glycoprotein (VLP-G), and LCMV GP (VLP-LCMV). Results indicate that both clomiphene and toremifene exhibit greater specificity to VLPs bearing the EBOV GP1,2 glycoprotein compared to VLPs bearing VSV-G or the LCMV GP. For each compound, assays with the different VLPs were performed in parallel. Error bars represent the SE for two or more replicates.